This wiki has undergone a migration to Confluence found Here
Difference between revisions of "PAC: FDA RFI"
Jump to navigation
Jump to search
Hbuitendijk (talk | contribs) |
Hbuitendijk (talk | contribs) |
||
| Line 1: | Line 1: | ||
| + | Return to [[Policy_Committee]] | ||
| + | |||
==Introduction== | ==Introduction== | ||
FDA issued a [[file:PAC FDA NoM RfC.pdf |Notice of Meeting with a Request for Comments]]. The comments are due October 5. | FDA issued a [[file:PAC FDA NoM RfC.pdf |Notice of Meeting with a Request for Comments]]. The comments are due October 5. | ||
Latest revision as of 20:21, 3 October 2012
Return to Policy_Committee
Introduction
FDA issued a File:PAC FDA NoM RfC.pdf. The comments are due October 5.
The 10 questions include a question on HL7 applicability, so it seems appropriate for HL7 to submit feedback to at least that question.
Plan
We wequest RCRIM and Pharmacy to provide input. Ed Tripp will coordinate.
Status
- 3-Oct-2012
- Ed created a draft document.
- This was reviewed by the Policy Committee off-line and accepted.
- Currently pending EC approval to be forwarded.
